$AKTX to advance lead candidate Coversin into Phase 3

/in /by

Akari Therapeutics (AKTX) had an End-of-Phase 2 meeting with the FDA and announced that they will advance lead candidate Coversin into Phase 3 development for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Q1 2018. 

Shares are up 6% in pre-market.

Read detail in our SeekingAlpha Marketplace Daily Pharma Scoop.